News | March 07, 2013

Data Demonstrate Orbital Atherectomy Safely Treats Calcified Coronary Arteries

CSI presents three-year Orbit I coronary data at CRT 2013

March 7, 2013 — Cardiovascular Systems Inc. (CSI) presented three-year data from its ORBIT I feasibility study of calcified coronary lesions during a poster session at the 2013 Cardiovascular Research Technologies (CRT) conference.

The ORBIT I study evaluated the safety of CSI’s orbital atherectomy system as a treatment for mild to severely calcified coronary arteries. Results from the 50-patient feasibility trial formed the basis for the ORBIT II pivotal trial. This three-year feasibility data shows that using CSI’s technology to treat calcified coronary arteries before stenting achieved not only early procedural success but also positive long-term outcomes.

“This case series demonstrates that CSI’s system can safely modify calcified lesions and facilitate stent delivery in this subset of difficult-to-treat patients,” said presenter Stevan Himmelstein, M.D., Baptist Memorial Hospital-Desoto, Memphis, Tenn. “Coronary artery disease, or CAD, is the leading cause of death for men and women in the United States. To have a potential solution for this pressing problem is encouraging.”

It is estimated that moderate to severe arterial calcium is present in nearly 40 percent of patients treated with interventional therapies. Calcium can lead to poor outcomes and higher treatment costs in coronary intervention when traditional therapies are used, including a significantly higher occurrence of death and major adverse coronary events.

The ORBIT I study consisted of 50 patients enrolled at two sites in India from May to June 2008. All subjects had at least one calcified coronary lesion with stenosis between 50 and 100 percent. Thirty-three of the 50 patients were enrolled at one of the two sites and were followed for three years post-procedure. The evaluated safety endpoint was major adverse cardiac event (MACE) rates.

Results show:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

In hospital

 

 

1 month post

 

 

6 months post

 

 

2 years post

 

 

3 years post

 

 

 

%

 

 

procedure

 

 

procedure

 

 

procedure

 

 

procedure

 

 

 

 

 

 

%

 

 

%

 

 

%

 

 

%

Overall MACE

 

 

6.1

 

 

9.1

 

 

12.1

 

 

15.2

 

 

18.2

Cardiac death

 

 

0

 

 

0

 

 

3.0

 

 

6.1

 

 

9.1

Non Q-Wave MI

 

 

6.1

 

 

9.1

 

 

9.1*

 

 

9.1

 

 

9.1

Q-Wave MI

 

 

0

 

 

0

 

 

0

 

 

0

 

 

0

TLR

 

 

0

 

 

3.0

 

 

3.0*

 

 

3.0

 

 

3.0

* One non Q-wave MI at 30 days that led to TLR

 

David L. Martin, CSI president and CEO, said, “Based on the results from our ORBIT I clinical study, demonstrating the safety in treating severely calcified coronary lesions, our orbital platform technology may be well suited for the removal of calcified plaque in coronary arteries. Our pivotal 443-patient ORBIT II PMA [premarket approval] clinical study has recently concluded and we are nearing completion of an FDA [U.S. Food and Drug Administration] submission to secure a coronary indication for our technology.”

CSI completed enrollment in the ORBIT II trial in November 2012. ORBIT II is CSI’s pivotal coronary IDE (investigational device exemption) trial studying this subset of patients. CSI is targeting the end of the quarter to submit its PMA package to the FDA.

For more information: www.csi360.com

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init